Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1980 Nov 1;152(5):1302-10.
doi: 10.1084/jem.152.5.1302.

Mechanisms of autoantibody production in autoimmune MRL mice

Mechanisms of autoantibody production in autoimmune MRL mice

D S Pisetsky et al. J Exp Med. .

Abstract

The quantitative expression of anti-DNA and anti-Sm antibodies has been investigated in autoimmune MRL-lpr/lpr and MRL-+/+ mice. Anti-Sm antibodies were detected in sera from 21/23 lpr/lpr and 10/16 +/+ mice, with individual animals showing striking variation in the time-course and magnitude of this autoantibody response. The peak antibody levels of the responding animals of each substrain did not differ significantly. For anti-DNA antibody, a different pattern of responsiveness was observed. Individual animals of each substrain produced very similar responses in terms of the magnitude and time-course of serum anti-DNA antibody. The differences in the peak levels of the two substrains were highly significant, with lpr/lpr mice demonstrating a much greater anti-DNA antibody response than +/+ mice. In lpr/lpr mice tested for both autoantibody systems, serum anti-DNA and anti-Sm antibodies showed distinct time-courses. These studies indicate that anti-DNA and anti-Sm antibodies are expressed independently in MRL mice, with the expression of anti-DNA, but not anti-Sm antibody markedly influenced by the presence of the 1pr gene. A fundamental difference in the mechanisms involved in the generation of anti-DNA and anti-Sm antibodies is suggested by the quantitative pattern of the two responses.

PubMed Disclaimer

References

    1. J Immunol. 1966 Mar;96(3):464-71 - PubMed
    1. J Clin Invest. 1966 Nov;45(11):1732-40 - PubMed
    1. N Engl J Med. 1968 Mar 7;278(10):533-8 - PubMed
    1. Clin Exp Immunol. 1968 Jun;3(5):375-83 - PubMed
    1. Nature. 1968 Sep 21;219(5160):1276-7 - PubMed

Publication types